Metsera Reports Highly Competitive Results from Ongoing Trial …
WEB1 day ago · Results include 7.5% reduction in body weight from baseline at day 36 Weight loss continued to at least 4 weeks after last dose administered MET-097, incorporating Metsera’s HALO™ platform ...
Metsera touts long-acting GLP-1 drug; Novartis strikes an AI deal
WEB1 day ago · Today, a brief rundown of news from Metsera and Novartis, as well as updates from Sanofi and Wave Life Sciences that you may have missed. Obesity drug startup Metsera on Tuesday reported its first clinical data since launching in April with $290 million in venture funding.The data come from a Phase 1 trial of a drug, MET-097, that’s designed to have longer-lasting effects than injectable GLP ...
Metsera GLP-1 data slice reveals 7.5% weight loss at 36 days
WEB1 day ago · Metsera links long-acting GLP-1 shot to 7.5% weight loss at 36 days, mulls monthly dosing. Recently debuted Metsera is unfolding some phase 1 data for its GLP-1 receptor agonist, revealing a 7.5% ...
Metsera Reports Highly Competitive Results from Ongoing
WEB1 day ago · NEW YORK--(BUSINESS WIRE)--Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced positive topline results from the Phase 1 clinical trial of MET-097, an ultra long-acting injectable, fully-biased GLP-1 receptor agonist.
New Weight Loss Biotech Metsera Stuns with 7.5% Weight Loss
WEB15 hours ago · Metsera said this was consistent with or better than marketed products, which include Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound, and other GLP-1/GIP compounds in clinical development. Cumulative weight loss in this dose group was 8.1% at day 57, four weeks after the last dose, which shows a …
Metsera Reports Highly Competitive Results from Ongoing Trial …
WEB19 hours ago · Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today announced positive topline results from the Phase 1 clinical trial of MET-097, an ultra long-acting injectable, fully-biased GLP-1 receptor agonist.
GLP-1 start-up Metsera launches with $290 million
WEBApr 18, 2024 · Metsera is advancing a suite of peptide and peptide-antibody conjugate drugs for weight loss and other indications, all based on GLP-1 agonists.
News - Metsera
WEBGLP-1 portfolio: led by an injectable, fully-biased GLP-1 receptor agonist in Phase 1 clinical trials with a potential class-leading duration of effect
Metsera Launches to Lead the Next Generation of Medicines for …
WEBApr 18, 2024 · GLP-1 portfolio: led by an injectable, fully-biased GLP-1 receptor agonist in Phase 1 clinical trials with a potential class-leading duration of effect
Metsera comes out of stealth with $290 million for obesity drugs
WEBApr 18, 2024 · So far, Metsera’s obesity drug pipeline includes a drug targeting the GLP-1 hormone receptor and another that spurs a hormone called amylin.
- Some results have been removed